Gradalis, Inc.

Strike Bio, Inc.

Nancy Smyth Templeton

Compositions and methods for tissue-specific targeted delivery of therapeutic agents through the use of tissue-specific peptidomimetic ligands are disclosed herein. The ligand comprises a composition of formula A-scaffold-A' and one or more hydrophobic anchors covalently linked to the scaffold. The A and A&#x2032; compounds linked to the scaffold comprise monovalent peptidomimetic compounds wherein each monovalent peptidomimetic compound is selected from the group consisting of fragments IKs, GKs, IDs, GSs, GTs, VSs, TKs, KTs, ARs, KIs, KEs, AEs, GRs, YSs, IRs, and morpholino.

Targeted delivery using tissue-specific peptidomimetic ligands

A process for the purification of plasmid DNA, the process comprising treating an aqueous composition containing plasmid DNA with a polypeptide obtained from an NST1 phage to digest colanic acid and separating the plasmid DNA from the treated aqueous composition.

Processes for the preparation of highly pure plasmid compositions by enzymatic digestion of colanic acid

The present disclosure generally relates to polypeptides having colanic acid-degrading activity and methods of using the same. Polynucleotides encoding such polypeptides are also described. The polypeptides may be used, for example, in processes for degrading colanic acid, processes for the removal of endotoxins from biological samples, and processes for purifying plasmid DNA.

Polypeptides having colanic acid-degrading activity

The present disclosure generally relates to processes employing polypeptides having colanic acid-degrading activity. The processes generally involve contacting a biological material with a polypeptide capable of digesting colanic acid. Additional process steps, such as chromatographic separation steps, are also described.

Growing community of inventors

Houston, TX, United States of America

Nancy Smyth Templeton